Biomnis partners with UNICANCER
for prognostic gene signature testing for breast cancer

Lyon, 20 January 2016 - Biomnis, the European leader in the sector of specialised medical pathology, has been chosen by the UNICANCER group to perform the Prosigna® gene signature assay for breast cancer prognosis.

In addition to a research program on therapeutic practices associated with genomic tests, Biomnis has been offering the Prosigna® gene signature assay to the 20 Centres de Lutte Contre Le Cancer which make up the UNICANCER group since December.

Assess the risk of recurrence for better therapeutic care

The Prosigna® gene signature assay for breast cancer prognosis has been developed based on the PAM 50 gene expression signature within cancerous breast tissue. This molecular signature is defined by the level of expression of 50 different genes in cancerous cells and makes it possible to assess the risk of distant tumour recurrence for a given patient.

As a result, by identifying patients who require chemotherapy and by preventing the administration of treatments with no beneficial effect, the Prosigna® assay makes it possible to provide individualised and personalised management of breast cancer, when treatment decisions are hard to make.

About Biomnis

European leader in the sector of specialised medical pathology, Biomnis carries out over 32,000 analyses per day from a range of over 2,500 tests available, including specialised tests for which the company has the appropriate authorisations. Founded in 1897 by Marcel Mérieux and dedicated to medical testing for over 100 years, Biomnis remains the leader in the field of specialised medical pathology in France. It has kept its position through continuous technological innovation and investment, particularly in areas such as female biology, oncology and personalised medicine, as well as chromosomal and molecular genetics. www.biomnis.com/international

About UNICANCER

UNICANCER is an umbrella organisation bringing together all of the French "Centres de lutte contre le cancer". These are non-profit private health care facilities dedicated exclusively to research and teaching in the field of oncology. Leading the way in the fight against cancer in France, the "Centres de lutte contre le cancer" work alongside the public hospital system and ensure that patients are treated in accordance with conventional tariffs, without any excess fees.

UNICANCER is both a hospital federation and a group of health care facilities.

UNICANCER in figures: 20 health care establishments, 18,000 employees, EUR 2.1 billion in revenue, more than 300 ongoing clinical trials, more than 120,000 patients a year. For more information: www.unicancer.fr

Press contact: Constance Lozet – 07 78 41 19 70 – biomnis@ekno.fr